CIK 0001390478
- Non-accelerated filer
- Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 646-200-5278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $716,682
- in 3 filings
Net −$716,682. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2013-11-26 | SCHWARTZ MARK W. Chief Operating Officer | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2013-11-26 | Ahn Mark J President and CEO | Grant or award · Stock Option (right to buy) | +600,000 | 600,000 | ||
| 2013-11-26 | Ahn Mark J President and CEO | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2013-11-26 | Nisi Rudolph Director | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2013-11-12 | Hillsberg Sanford Director | Gift | −37,001 | 93,375 | ||
| 2013-10-11 | Hillsberg Sanford Director | Grant or award | +2,630 | 17,974 | ||
| 2013-10-11 | SCHWARTZ MARK W. EVP, Chief Operating Officer | Grant or award | +7,349 | 504,009 | ||
| 2013-06-30 | Ahn Mark J President & CEO | Other acquisition | +7,862 | $1.35 | $11K | 108,108 |
| 2013-06-30 | SCHWARTZ MARK W. EVP, Chief Operating Officer | Other acquisition | +7,862 | $1.35 | $11K | 496,660 |
| 2013-06-30 | Dunlap Ryan Principal Accounting Officer | Other acquisition | +1,369 | $1.35 | $2K | 2,615 |
| 2013-06-04 | Hillsberg Sanford Director | Grant or award | +9,344 | 145,720 | ||
| 2013-06-04 | SCHWARTZ MARK W. EVP, Chief Operating Officer | Grant or award | +26,110 | 488,798 | ||
| 2013-06-04 | Hillsberg Sanford Director | Grant or award | +9,327 | 145,703 | ||
| 2013-04-26 | Ashton William Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2013-01-29 | Nisi Rudolph Director | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2013-01-29 | Chin Richard Director | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2013-01-29 | GALLIKER STEPHEN S Director | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2013-01-29 | Ahn Mark J President & CEO | Grant or award · Stock Option (right to buy) | +650,000 | 650,000 | ||
| 2013-01-29 | SCHWARTZ MARK W. EVP, Chief Operating Officer | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2013-01-29 | MAZANET ROSEMARY Chief Medical Officer | Grant or award · Stock Option (right to buy) | +450,000 | 450,000 |
Page 18 of 29 · 580 trades